Clinical Trial Detail

NCT ID NCT02771197
Title Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Northside Hospital, Inc.
Indications

acute myeloid leukemia

Therapies

Fludarabine + Melphalan

Pembrolizumab

Age Groups: adult

No variant requirements are available.